碩世生物(688399.SH):擬設立境外孫公司
格隆匯8月8日丨碩世生物(688399.SH)公佈,公司爲達成公司國際化發展戰略目標,深入挖掘市場潛力,充分藉助巴西在國際貿易領域的優勢,有效應對未來可能出現的貿易風險,提升公司整體訂單交付能力,更好地滿足客戶需求並拓展國際市場,公司擬通過全資控股子公司碩世生物香港有限公司在巴西投資設立海外孫公司。投資總額300萬美元,經營範圍:醫療器械產品研發、生產、註冊、貿易、技術諮詢服務等。
公司設立境外孫公司,核心目的在於深化國際業務佈局:一方面順應國際貿易發展趨勢,藉助巴西在國際貿易領域的區位與資源優勢,深入挖掘海外市場潛力,進一步拓展國際市場份額;另一方面通過優化業務佈局,有效應對未來可能出現的貿易風險,提升公司整體訂單交付能力,更好地滿足海外客戶需求,促進與海外客戶的交流合作,最終實現盈利能力的提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.